


# Ca-MRSA Update- Hand Infections

Washington Hand Society

September 19, 2007



# Resistant Staph. Aureus

- Late 1940's -50% S.Aureus resistant to PCN
- 1957- 80/81 strain- of S.A. highly virulent and easily transmissible strain spreads world-wide
- 80/81 carried nasally, caused septicemia in 30% of all carriers, responsible for all epidemic outbreaks in US maternity wards and 50% of all hospital based outbreaks in the UK
- 1961-incidence died down- advent of methicillin

# Methicillin Resistance

- 1960-three resistant isolates discovered, 6 months after Meth. was introduced.
- 1967- resistant strains found all over Europe and India
- 1981- First Gentamycin resistant SA in US and Europe
- By 1990- sixteen strains of MRSA identified

# Ca- MRSA

- 1993- Western Australia among Aborigines not exposed to health care system.
- Entirely different class of SA from hospital acquired

# Staph Aureus resistance timeline



- 1941** – Introduction of penicillin into treatment of infectious disease
- 1944** – *S. aureus* penicillin resistant
- 1960** – New penicillinase-resistant drugs are used to fight staph infections (i.e. methicillin)
- 1975** – Methicillin-resistant strains of *S. aureus* emerge
- 1988** – 2.4% *S. aureus* are methicillin-resistant
- 1989** – .3% enterococci vancomycin-resistant
- 1991** – 29% *S. aureus* methicillin-resistant
- 1993** – 7.9% enterococci vancomycin-resistant
- 1996** – *S. aureus* strain with intermediate vancomycin resistance reported in Japan
- 1998** – Man in New York dies from a staph infection


# Ca MRSA vs. HaMRSA

- Ca-more susceptible to non B -lactam antibiotics
- Differ in genotype sequences USA-300/100
- Differing Meth. resistant “cassettes” (plasmids): SCCmec type IV
- Panton-Valentine virulence factor

# Ha-MRSA long sequences

# Ca-MRSA short sequences





*Figure 3. Comparison of antibiotic susceptibilities between CA and HA MRSA isolates.*



# Populations Reported: high intensity physical contact

- IV Drug users
- Homeless
- Gay Men
- Prison inmates
- Military recruits
- Children in Day Care
- “Contact” Sports Teams

Characteristic	CA MRSA n = 26 (%)	HA MRSA n = 25 (%)
<b>Age, years *</b>		
Mean (range)	38.7 (4-82)	59.7 (20-84)
<b>Sex</b>		
Male	17 (65)	9 (36)
Female	9 (35)	16 (64)
<b>Race</b>		
Caucasian	11 (42)	16 (64)
African-American	13 (50)	9 (36)
Hispanic	2 (8)	0
<b>Comorbidities</b>		
CAD <sup>1</sup> ,*	2 (7.5)	13 (52)
DM <sup>2</sup> ,*	0	11 (44)
ESRD/HD <sup>3</sup> ,*	0	5 (20)
Malignancy*	1 (3.8)	6 (24)
IVDA <sup>4</sup>	3 (11.5)	2 (8)
HIV <sup>5</sup>	2 (7.5)	0
Various	3 (11.5)	4 (16)
None known*	16 (61.5)	0
<b>Site of infection</b>		
Scalp/face	3 (11.5)	4 (16)
Upper extremities	3 (11.5)	2 (8)
Lower extremities*	10 (38.5)	3 (12)
Abdomen/Chest	0	3 (12)
Spine*	1 (4)	8 (32)
Various	0	1 (4)
Unknown	9 (34.5)	4 (16)

<sup>1</sup> Coronary artery disease, <sup>2</sup> Diabetes mellitus, <sup>3</sup> End-stage renal disease / Hemodialysis, <sup>4</sup> Intravenous drug abuse, <sup>5</sup> Human immunodeficiency virus;  
\* P-value<0.05 (statistical comparison was performed by chi square analysis)

Table 1. Patient Characteristics

# St Louis Rams



# Kazakova NEJM 2005

## single clone MRSA

- 2003 season 5/58 players on the Rams got MRSA skin and soft tissue infections
- All abscesses occurred at the site of previous injury i.e. turf burns and lacerations uncovered areas
- Transmitted by close personal contact from infected lesion or secretions-lineman, linebackers
- Use of showers, whirlpools, and shared towels and clothing, and weight room surfaces not shown to transmit.
- Teams playing the Rams got sporadic cases

# Nasal Carriers?

- From 2000-2005 numerous sports teams from High School to the pro's
- Wrestling, soccer, football, rugby, basketball
- Originally thought to be carried nasally
- Mupirocin ointment given nasally ineffective in stemming outbreaks
- Role unclear

# Vancomycin Resistance


- 1997- first HaVRSA reported
- 2002-first CaVRSA –Detroit drug user
- Conjugative transposition from co-infected patient with VRE. New York City
- van-A gene transfer from enterococcus
- VISA (intermediate sensitivities MIC>4mg/L) not clinically responsive
- Now multiple strains of VRSA identified

# Lysis of cell wall




**Figure1. Trans electron micrograph of Staphylococcus aureus and antibiotic effect.**

# Horizontal gene transfer



# Mechanism of Resistance



- SCCmec gene produces PBP2a- cell wall B lactam insensitive




# Today


- MRSA is most common antibiotic resistant pathogen in the world
- World wide rates are soaring
- 20% of all MRSA are community acquired



# Ca-MRSA rate Canada



# World-wide prevalence by country



# Moran NEJM 2006

- 11 university affiliated ER's around the US
- 320/422 patients with skin-st infections were S.A. (76%)
- MRSA were 59% (15-74%)
- USA-300 -97%
- SCCmec type IV, PV leukocidin toxin 98%

# Ca- sensitivities

- Vancomycin ?
- Clindamycin 95%
- TMP-SMX + rifampin 100%
- Tetracyclenes (doxycyclene,minocyclene)  
92%
- Flouroquinolones-60%

# Clinical Manifestations

- Skin and soft tissue infections
- Septic arthritis
- Bacteremia
- Toxic Shock Syndrome
- Necrotizing fasciitis/cellulitis/pneumonia
- Traumatic wound infections

# CDC Criteria

- Dx. made in outpatient setting or + culture with 48 hrs of hospitalization
- No hx of MRSA infection or colonization
- No hx. Of admission to health-care facility in past year or dialysis or surgery
- No indwelling catheters or implants

# Diagnosis


- Detailed History r/o spider bites
- Local cultures
- Pulsed -field gel electrophoresis
- Recurrent skin infections not responsive to B lactam antibiotics
- “Polymerase chain reaction amplification”  
to detect virulence factors



# Brown Recluse spider bites



# Gel electrophoresis



M-marker; 1-SCCmec type I; 2-SCCmec type II; 3-SCCmec type III;  
4-SCCmec type IV; 5-blank; 6-PVL negative; 7-PVL positive;  
162bp: SCCmec gene internal control; 495bp: SCCmec type I top band;  
433bp: PVL

*Figure 1. Detection of SCCmec types I-IV and PVL by PCR assays in CDC control isolates*

40531800130

DIS-M20860100

Page:

Order No: 3

6207 - CULTURE WOUND SUPERFICIAL W/SMEAR

Specimen: No Description Test Status: F Collection Date/Time: 11/14/05 10

Source: FINGR  
Site: Left

Collected: 11/14/05 10:30  
Received : 11/14/05 15:30

GRAM STAIN DIRECT FINAL 11/14/05 17:45  
11/14/05 Rare WBC's  
Many Gram positive cocci in pairs and clusters

CULTURE WOUND SUPERFICIAL W/SMEAR FINAL 11/16/05 13:16  
Isolate: Staphylococcus aureus  
Many  
\*Methicillin Resistant - precludes the use of all currently available beta lactam antibiotics.\*  
This organism does not demonstrate inducible clindamycin resistance in vitro.

Organism	S.aureu	
	MIC	INT
Clindamycin	<=0.5	S
Erythromycin	>4	R
Linezolid	<=2	S
Oxacillin	>2	R
Synercid (Quinupristin/Da	<=1	S
Trimeth/Sulfa	<=2/38	S
Vancomycin	<=2	S

S=SUSCEPTIBLE I=INTERMEDIATE R=RESISTANT POS=POS

End of Report!

# Treatment-1

- If local area has high incidence of MRSA routine use of B- lactam antibiotics as a first- line drug may not be indicated
- Localized skin infection can be treated with I&D?
- 95% of MRSA sensitivity to TMP-SMZ but double the dose is used, can be used with Rifampin to lower “inducible resistance”


# Treatment- 2

- Clindamycin –(children)
- Flouroquinolones- ciprofloxacin, (moxifloxacin, gatifloxacin)--resistance
- Tetracyclenes (minocyclene, doxycyclene)
- Vancomycin –mainstay
- Linezolid best for VRSA
- ?daptomycin,tigecyclene-new

# Ceftobiprole

- A new class of cephalosporin binds to penicillin binding protein PBP2 allowing the B-lactam to break down the cell wall
- Is refractory to development of resistance by Staph.....so far

# Treatment algorithm



\*Immunocompromised patients may NOT show typical signs and symptoms of infections, but may require a limited course of systemic antibiotics to control critical colonization of MRSA in their wounds.

# Necrotizing Cellulitis





# Necrotizing Fasciitis



# Finger lesion- Patient claimed a spider bite



# Wide excision needed, not an "I&D"



# Prevention in group settings

- Personal and environmental hygiene
- Rigorous laundry procedures
- All cuts and open wounds need to be covered
- “Nasal” prophylaxis



# One article in JHS July 2000

- Karanas and Bogdan
- 4 cases of skin infection by Ca-MRSA treated with I&D and Vancomycin  
uncomplicated course

# My experience

- 7 cases in the past year
- 5 finger lesions, 1 hand, 1 forearm lesion
- 3 treated with IV Vanco as OPD
- 4 with Bactrim po
- All resolved

# This is just the tip of the iceberg

- A recent study found that one in five stethoscopes used by clinicians were contaminated with Staph Aureus, including one that harbored MRSA

